POLA2

Across TCGA pan-cancer cohorts, POLA2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated POLA2 data layer compared with 28 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher POLA2 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated POLA2 expression acts as an unfavorable survival marker, although some lineages such as LUAD and LSCC show a favorable association.

LUAD, LSCC, and GBM are the cancer types where POLA2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Quartile	II,III,IV	0.897	0.336	.008	25	view →
LSCC	DFS	Median	All	0.881	0.666	.007	16	view →
GBM	OS	Median	All	0.778	1.000	<.001	7	view →
CCRCC	DFS	Quartile	II,III,IV	0.207	0.817	.038	3	view →
PDAC	DFS	Tertile	All	0.764	1.000	.049	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

POLA2–LUAD (OS)

Open the LUAD breakdown →